Disc Medicine, Inc. (IRON)
Automate Your Wheel Strategy on IRON
With Tiblio's Option Bot, you can configure your own wheel strategy including IRON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IRON
- Rev/Share 0.0
- Book/Share 17.5353
- PB 3.7684
- Debt/Equity 0.0503
- CurrentRatio 32.1068
- ROIC -0.2624
- MktCap 2297309592.0
- FreeCF/Share -3.8703
- PFCF -16.9473
- PE -15.919
- Debt/Assets 0.0465
- DivYield 0
- ROE -0.266
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IRON | Truist | -- | Buy | -- | $86 | July 21, 2025 |
| Resumed | IRON | Morgan Stanley | -- | Overweight | -- | $85 | July 3, 2025 |
| Resumed | IRON | Raymond James | -- | Strong Buy | -- | $89 | June 11, 2025 |
| Initiation | IRON | TD Cowen | -- | Buy | -- | -- | Feb. 27, 2025 |
| Initiation | IRON | Jefferies | -- | Buy | -- | $89 | Oct. 23, 2024 |
| Initiation | IRON | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Initiation | IRON | Wells Fargo | -- | Overweight | -- | $75 | Aug. 22, 2024 |
News
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). Disc submitted the NDA under the FDA's accelerated approval pathway using reduction of protoporphyrin IX (PPIX) as a surrogate endpoint and requested a Priority Review based on bitopertin's potential to address the …
Read More
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics.
Read More
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2025 Congress, which will be held in Milan, Italy on June 12-15, 2025.
Read More
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 68.8% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a recap of recent program and corporate developments.
Read More
Disc Medicine to Participate in Upcoming Investor Conferences
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences:
Read More
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
About Disc Medicine, Inc. (IRON)
- IPO Date 2020-08-12
- Website https://www.discmedicine.com
- Industry Biotechnology
- CEO John D. Quisel
- Employees 94